Updated

Updated · Yahoo Finance · Aug 14

Elanco Raises 2026 Outlook After Q2 Revenue Beats by 4.2% on Zenrelia, Credelio Quattro

Updated

Updated · Yahoo Finance · Aug 14

Elanco Raises 2026 Outlook After Q2 Revenue Beats by 4.2% on Zenrelia, Credelio Quattro

Q: What hidden clinical advantage is causing veterinarians to rapidly switch to Elanco's new parasite prevention drugs?

The key clinical edge appears to be **speed and consistency of tick kill**, especially in Credelio Quattro’s lotilaner-based formula. Elanco has highlighted peer-reviewed data showing the drug significantly reduces black-legged ticks within **8 hours** and lone star ticks within **12 hours**, while maintaining that rapid kill through **Day 28**. That matters because Lyme disease transmission typically occurs **24 to 48 hours after tick attachment**, so faster kill can materially lower infection risk. That performance gives veterinarians a practical reason to switch: it is not just another broad-spectrum parasite tablet, but one with evidence of acting faster than key rivals such as Simparica Trio and NexGard Plus in head-to-head comparisons. Elanco has also emphasized that Credelio Quattro carries an **FDA-approved Lyme disease prevention claim**, which strengthens its clinical positioning in areas where tick-borne disease is a major concern. In other words, the “hidden” advantage is not mainly price or marketing. It is that veterinarians are seeing a product with a differentiated medical story: rapid tick kill, sustained protection across the full dosing interval, and a direct tie to prevention of a high-profile disease. That combination helps explain why clinic adoption has expanded quickly and why management says veterinarian confidence is rising.

2 articles · Updated · Yahoo Finance · Aug 14

$1.37 billion in Q2 revenue topped analyst estimates of $1.31 billion, while adjusted EPS of $0.34 beat the $0.27 consensus as Elanco posted 10.2% year-on-year growth.
Zenrelia and Credelio Quattro drove the outperformance, with management citing strong U.S. and international execution, wider retail availability and deeper market penetration across pet health and farm animal products.
Elanco lifted full-year guidance to $5.12 billion in revenue, $1.13 adjusted EPS and $1.02 billion EBITDA at the midpoint, all above its prior outlook.
Margins also improved, with operating margin rising to 8% from 6.8% a year earlier and adjusted EBITDA reaching $288 million for a 21.1% margin.
Management told analysts durable demand, veterinarian adoption and direct-to-consumer marketing are still supporting share gains in dermatology and parasiticides despite competitive pricing pressure.